Study guide

2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria

ARRT Bone Densitometry Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation & the ARRT Blueprint

1.1 About the ARRT Bone Densitometry Examination 1.2 Eligibility, Structured Education, and Clinical Experience

2 Chapter 2: Osteoporosis, Bone Biology & Risk Factors

2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria 2.2 Bone Functions, Structural Anatomy, and Bone Types 2.3 Bone Cells, the Remodeling Cycle, and Calcium Homeostasis 2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications

3 Chapter 3: Indications, Prevention & Treatment

3.1 The Bone Mass Measurement Act: Covered Indications and Coding 3.2 Prevention: Nutrition, Exercise, Smoking Cessation, and Fall Prevention 3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents

4 Chapter 4: Patient Preparation, Support & Radiation Safety

4.1 Patient Support, Disabilities, Ergonomics, and Transfer Techniques 4.2 Patient Instructions: Explaining the Exam, Dose, Duration, and Motion Control 4.3 Patient History, Contraindications, and Pregnancy Screening 4.4 Scan Preparation: Patient Data Entry, Artifact Removal, and Infection Control 4.5 Radiation Safety in DXA: ALARA, Distance, and Dose Levels

5 Chapter 5: DXA Physics & Instrumentation

5.1 Physical Principles of Dual-Energy X-ray Absorptiometry 5.2 Beam Geometries: Pencil Beam and Fan Beam Systems 5.3 Fan-Beam Geometry: Source–Object–Detector Distances, Magnification, and Centering 5.4 The Scan Analysis Algorithm: Soft Tissue, Bone Edge Detection, BMC, Area, and BMD

6 Chapter 6: Measuring & Reporting Bone Mineral Density

6.1 Statistics for Densitometry: Mean, Standard Deviation, and Coefficient of Variation 6.2 T-Scores, Z-Scores, and Reference Database Selection 6.3 Clinical Indications for BMD Testing and the FRAX Tool 6.4 Vertebral Fracture Assessment and Trabecular Bone Score 6.5 Whole Body DXA, Body Composition, and Pediatric Scanning

7 Chapter 7: Quality Control, Precision & Equipment Management

7.1 Accuracy, Precision, and the Sources of Precision Error 7.2 Daily Quality Control, Phantoms, and Control Charts 7.3 In Vivo Precision Studies and RMS-SD Calculation 7.4 Determining and Applying the Least Significant Change 7.5 Maintenance, Repair, Relocation, Cross-Calibration, and Software Upgrades

8 Chapter 8: DXA Informatics & Data Management

8.1 DXA Informatics, DICOM, PACS, and Data Management

9 Chapter 9: Lumbar Spine DXA

9.1 Lumbar Spine Anatomy, Landmarks, and Regions of Interest 9.2 Lumbar Spine Scan Acquisition and ROI Edge Placement 9.3 Lumbar Spine: Compensating for Body Habitus, Variant Anatomy, Pathology, and Low Bone Density 9.4 Lumbar Spine Positioning: The Leg Block, Centering, and Common Challenges 9.5 Lumbar Spine Problems: Poor Bone Edge Detection and Obscured Intervertebral Spaces 9.6 Lumbar Spine: Variant Anatomy, Fractures, Degenerative Pathology, Calcification, and Surgery 9.7 Lumbar Spine Analysis: Vertebral Exclusion and Reporting Rules 9.8 Lumbar Spine Follow-Up Scans and Rate of Change

10 Chapter 10: Proximal Femur DXA

10.1 Proximal Femur Anatomy, Landmarks, and Regions of Interest 10.2 Femur Selection: Right, Left, and Dual Femur Scanning 10.3 Proximal Femur Scan Parameters and Compensation 10.4 Proximal Femur Positioning: Neck Rotation, Shaft Placement, and Positioning Aids 10.5 Proximal Femur Problems: Ischium, Short Neck, Arthritis, Fracture, and Hardware 10.6 Femoral ROI Analysis: Femoral Neck, Total Hip, and Ward's Area 10.7 Proximal Femur Follow-Up Scans and Rate of Change

11 Chapter 11: Forearm DXA

11.1 Forearm Anatomy, Landmarks, and Adjacent Structures 11.2 Forearm Indications and Side Selection 11.3 Forearm Length Measurement, Scan Parameters, and Positioning 11.4 Forearm Regions of Interest: One-Third, Mid, Ultradistal, and Total 11.5 Forearm Problems: Edge Detection, Artifacts, Low Bone Density, and Joint Disease 11.6 Scan Analysis: Region Placement, Window Level, and Reported Values 11.7 Forearm Follow-Up Scans and Rate of Change

12 Chapter 12: Cross-Site Artifacts & Clinical Integration

12.1 Recognition, Impact, and Management of DXA Artifacts 12.2 Clinical Interpretation, Serial Comparison, and Reporting

2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria

Key Takeaways Explain This Topic AI

Osteoporosis is defined as a systemic skeletal disorder characterized by compromised bone strength predisposing to an increased fracture risk, where bone mineral density accounts for roughly 60% to 70% of skeletal breaking strength and bone quality accounts for the remainder.

Primary osteoporosis comprises Type I (postmenopausal, high-turnover trabecular bone loss driven by acute estrogen withdrawal) and Type II (senile/age-related, proportionate cortical and trabecular loss driven by osteoblast senescence and secondary hyperparathyroidism).

Secondary osteoporosis arises from identifiable systemic diseases, malabsorptive conditions, endocrine disorders, or medication therapies such as systemic glucocorticoids.

The World Health Organization (WHO) classifies central DXA T-scores into four diagnostic tiers: Normal (T >= -1.0), Low Bone Mass / Osteopenia (-1.0 > T > -2.5), Osteoporosis (T <= -2.5), and Severe/Established Osteoporosis (T <= -2.5 with one or more fragility fractures).

A fragility fracture is clinically defined as a fracture sustained from low-energy mechanical force equivalent to a fall from a standing height or less, commonly involving the hip, spine, distal forearm, or proximal humerus.

Last updated: September 2026

2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria

Quick Answer: Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Bone strength integrates bone mineral density (BMD), which accounts for roughly 60% to 70% of skeletal breaking strength in mechanical testing, and bone quality, which accounts for the remainder. The World Health Organization (WHO) classifies central DXA T-scores as Normal ( T ≥ − 1.0 T \ge -1.0 T ≥ − 1.0 ), Low Bone Mass / Osteopenia ( − 1.0 > T > − 2.5 -1.0 > T > -2.5 − 1.0 > T > − 2.5 ), Osteoporosis ( T ≤ − 2.5 T \le -2.5 T ≤ − 2.5 ), or Severe Osteoporosis ( T ≤ − 2.5 T \le -2.5 T ≤ − 2.5 plus fragility fracture). Primary osteoporosis is divided into Type I (postmenopausal, estrogen withdrawal, rapid trabecular loss) and Type II (senile, cortical and trabecular thinning, osteoblast senescence, impaired calcium absorption).

Defining Osteoporosis: Bone Strength, Density, and Quality

The National Institutes of Health (NIH) and the World Health Organization (WHO) define osteoporosis as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and fracture susceptibility. For densitometry technologists, understanding that bone strength depends on both density and material quality is fundamental: Bone Strength = Bone Mineral Density (BMD) + Bone Quality \text{Bone Strength} = \text{Bone Mineral Density (BMD)} + \text{Bone Quality} Bone Strength = Bone Mineral Density (BMD) + Bone Quality

Bone Mineral Density (BMD): Quantified by dual-energy X-ray absorptiometry (DXA) in grams of mineral per square centimeter of projected area ( g/cm 2 \text{g/cm}^2 g/cm 2 ). In mechanical testing, areal BMD accounts for approximately 60% to 70% of ultimate skeletal breaking strength.

Bone Quality: Encompasses architectural and material properties not captured by 2D DXA: trabecular microarchitecture (connectivity and plate-to-rod transitions), cortical geometry and porosity, collagen cross-linking (enzymatic pyridinoline vs. non-enzymatic glycation products), mineralization degree, and accumulated microdamage.

Primary Osteoporosis: Type I vs. Type II Pathophysiology

Primary osteoporosis occurs without an underlying systemic medical disorder. Albright, and later Riggs and Melton, classified primary osteoporosis into Type I (postmenopausal) and Type II (senile or age-related):

Type I Osteoporosis (Postmenopausal)

Epidemiology: Manifests in women aged 50 to 70 within 15 to 20 years after menopause (female-to-male ratio ~6:1).

Etiology: Acute estrogen withdrawal. Estrogen suppresses bone resorption by limiting pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and maintaining osteoprotegerin (OPG). Estrogen deficiency surges RANKL, driving osteoclast proliferation, activation, and survival.

Remodeling Dynamics: Acute high-turnover state where osteoclastic resorption outpaces osteoblast formation.

Compartmental Loss: Selective, rapid loss of trabecular bone (3% to 5% annually in early postmenopause), causing trabecular thinning and horizontal plate perforation.

Fracture Profile: Vertebral crush/wedge fractures and distal forearm (Colles') fractures.

Type II Osteoporosis (Senile / Age-Related)

Epidemiology: Manifests in elderly men and women aged 70 and older (female-to-male ratio ~2:1).

Etiology: Cellular senescence and multi-organ endocrine aging:

Osteoblast Senescence: Mesenchymal stem cells shift toward adipogenesis; osteoblasts exhibit blunted replication and matrix synthesis.

Impaired Calcium-PTH Axis: Declining renal 1-alpha-hydroxylase reduces calcitriol [ 1 , 25 ( OH ) 2 D 1,25(\text{OH})_2\text{D} 1 , 25 ( OH ) 2 ​ D ] synthesis. Impaired intestinal calcium absorption triggers secondary hyperparathyroidism, persistently elevating parathyroid hormone (PTH) to resorb skeletal calcium.

Sex Steroid Deficiency: Gradual loss of estrogens and androgens in aging individuals.

Compartmental Loss: Slow, steady bone loss (~0.5% to 1% annually) affecting both cortical and trabecular compartments proportionately, with cortical thinning and Haversian canal porosity.

Fracture Profile: Hip fractures (femoral neck and intertrochanteric), pelvis, proximal humerus, and multiple vertebral wedge fractures causing thoracic kyphosis ("dowager's hump").

  • Feature Type I: Postmenopausal Type II: Senile / Age-Related
  • Typical Age Range 50–70 years ≥ 70 \ge 70 ≥ 70 years
  • Gender Ratio (F:M) ~6:1 (predominantly female) ~2:1 (both sexes affected)
  • Primary Etiology Acute estrogen deficiency Osteoblast senescence & secondary hyperparathyroidism

Bone Turnover State High-turnover (resorption >> formation) Low-to-normal turnover (decreased osteoblast output)

  • Primary Compartment Trabecular bone (accelerated loss) Cortical and trabecular bone proportionately
  • Annual Rate of Loss 3%–5% per year postmenopause 0.5%–1% per year continuously
  • Characteristic Fractures Vertebrae (crush) and distal radius Hip (femoral neck/trochanter), pelvis, humerus
  • Secondary Osteoporosis Overview

Secondary osteoporosis refers to bone loss resulting from an identifiable systemic medical condition, endocrine pathology, malabsorption disorder, or medication regimen. Secondary causes occur in up to 30% of postmenopausal women and over 50% of men presenting with osteoporosis. Key etiologies—such as hyperparathyroidism, celiac disease, and systemic glucocorticoid therapy—are detailed in Section 1.3.

WHO Diagnostic Criteria Based on T-Score

The World Health Organization (WHO) established diagnostic criteria for postmenopausal women and men aged 50 and older using central DXA (lumbar spine, proximal femur, or forearm). The T-score reflects the standard deviations (SD) a patient's BMD deviates from the mean of a healthy young-adult reference population (aged 20–29, using the NHANES III female reference database for the hip): T-score = Patient BMD − Young-Adult Mean BMD Young-Adult Standard Deviation \text{T-score} = \frac{\text{Patient BMD} - \text{Young-Adult Mean BMD}}{\text{Young-Adult Standard Deviation}} T-score = Young-Adult Standard Deviation Patient BMD − Young-Adult Mean BMD ​

Each 1.0 SD decrease in T-score roughly doubles to triples relative fracture risk.

Category DXA T-Score Threshold Clinical Interpretation

Normal T ≥ − 1.0 T \ge -1.0 T ≥ − 1.0 SD BMD within 1.0 SD of young-adult mean; baseline fracture risk.

Low Bone Mass (Osteopenia) − 1.0 > T > − 2.5 -1.0 > T > -2.5 − 1.0 > T > − 2.5 SD (-1.1 to -2.4) Moderate fracture risk; lifestyle optimization and FRAX evaluation indicated.

Osteoporosis T ≤ − 2.5 T \le -2.5 T ≤ − 2.5 SD BMD ≥ 2.5 \ge 2.5 ≥ 2.5 SD below young-adult mean; high fracture risk; pharmacotherapy indicated.

Severe / Established T ≤ − 2.5 T \le -2.5 T ≤ − 2.5 SD plus ≥ 1 \ge 1 ≥ 1 fragility fracture Marked skeletal fragility with documented low-trauma fracture; extreme imminent fracture risk.

Fragility Fractures: Definition and Diagnostic Rules

A fragility fracture (low-trauma fracture) is clinically defined as a fracture sustained from mechanical forces that would not fracture healthy bone—specifically, trauma resulting from a fall from a standing height or less , or occurring during routine daily activities without external trauma (e.g., coughing, turning, or lifting light objects).

Major Osteoporotic Fracture (MOF) Sites: The four hallmark sites tracked in clinical risk models (e.g., FRAX) are: 1) Vertebrae (clinical or morphometric compression), 2) Hip (femoral neck, intertrochanteric, subtrochanteric), 3) Distal forearm (distal radius / Colles' fracture), and 4) Proximal humerus.

Anatomical Exclusions: Fractures of the skull, facial bones, cervical spine, hands, metacarpals, feet, and metatarsals are explicitly excluded from the definition of osteoporotic fragility fractures because they typically reflect high-energy trauma, local stress, or distinct biomechanical forces rather than generalized skeletal fragility.

The Imminent Fracture Cascade: An initial fragility fracture doubles to quadruples future fracture risk, with up to 50% of secondary fractures occurring within the first 12 to 24 months ( imminent fracture risk ).